Search - tctmd.com

Displaying 661 - 680 of 11309

Sort: Relevancy | Date

Rosuvastatin Bests Atorvastatin for Reducing CVD Risk: Registry Data

News Daily News

Rosuvastatin Bests Atorvastatin for Reducing CVD Risk: Registry Data

Michael O'Riordan

November 07, 2024

Advocates Urge Heat Maps and Grassroots Campaigns to Improve PAD Care

News Conference News VIVA 2024

Advocates Urge Heat Maps and Grassroots Campaigns to Improve PAD Care

November 07, 2024

Amputations Still Avoided With Flow-Diverting Therapy for CLTI at 2 Years: PROMISE II

News Conference News VIVA 2024

Amputations Still Avoided With Flow-Diverting Therapy for CLTI at 2 Years: PROMISE II

November 06, 2024

Machismo in Youth Linked to Fewer CVD Diagnoses, Less Treatment in Adulthood

News Daily News

Machismo in Youth Linked to Fewer CVD Diagnoses, Less Treatment in Adulthood

November 06, 2024

Co-STAR Hints That Colchicine May Curb Rhythm Disturbances After TAVI

News Conference News TCT 2024

Co-STAR Hints That Colchicine May Curb Rhythm Disturbances After TAVI

Michael O'Riordan

November 06, 2024

After TAVI, Single Antiplatelet Better Than Dual: TRITAVI Registry

News Conference News TCT 2024

After TAVI, Single Antiplatelet Better Than Dual: TRITAVI Registry

Yael L. Maxwell

November 05, 2024

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

News Conference News VIVA 2024

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

November 05, 2024

Vascular Closure via Suture/Plug Combo Reduces Complications: ACCESS-TAVI

News Conference News TCT 2024

Vascular Closure via Suture/Plug Combo Reduces Complications: ACCESS-TAVI

November 04, 2024

PAD Patients’ Views on Decisions and Outcomes Hinge on Sex, Race/Ethnicity: ELEGANCE

News Conference News TCT 2024

PAD Patients’ Views on Decisions and Outcomes Hinge on Sex, Race/Ethnicity: ELEGANCE

November 04, 2024

CONFIRM2 Shows Power of AI-QCT to Use Plaque Features to Predict CAD Events

News Conference News TCT 2024

CONFIRM2 Shows Power of AI-QCT to Use Plaque Features to Predict CAD Events

Yael L. Maxwell

November 01, 2024

TCTMD’s Top 10 Most Popular Stories for October 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2024

November 01, 2024

Pooled All-Female Analysis Support Benefits of TAVI Over SAVR

News Conference News TCT 2024

Pooled All-Female Analysis Support Benefits of TAVI Over SAVR

November 01, 2024

Embolic Protection Benefits Varied by Geography in PROTECTED TAVR

News Conference News TCT 2024

Embolic Protection Benefits Varied by Geography in PROTECTED TAVR

October 31, 2024

News Conference News TCT 2024

Bleeding After MCS in DanGer Shock: When, Where, and What to Do?

October 31, 2024

QFR No Match for FFR in Guiding Revascularizations: FAVOR III Europe

News Conference News TCT 2024

QFR No Match for FFR in Guiding Revascularizations: FAVOR III Europe

October 30, 2024

Preprocedural AI-QCA Matches OCT-Guided PCI for Noncomplex Lesions

News Conference News TCT 2024

Preprocedural AI-QCA Matches OCT-Guided PCI for Noncomplex Lesions

Yael L. Maxwell

October 30, 2024

TRISCEND II: Full Results a Win for TTVR in Severe Tricuspid Regurgitation

News Conference News TCT 2024

TRISCEND II: Full Results a Win for TTVR in Severe Tricuspid Regurgitation

Michael O'Riordan

October 30, 2024

ACURATE IDE Trial Misses Primary Endpoint in All-Risk TAVI Patients

News Conference News TCT 2024

ACURATE IDE Trial Misses Primary Endpoint in All-Risk TAVI Patients

October 30, 2024

Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows

News Conference News TCT 2024

Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows

Michael O'Riordan

October 29, 2024

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

News Conference News TCT 2024

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

October 29, 2024

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.